Drugs / pyrrolizidine
last change Jun 2026 re-read 3 minutes ago

pyrrolizidine

Developed for
salivary gland cancer
Investigated by
Peking Union Medical College

Trials 1

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05898373 Jun 2023 → Jun 2025 salivary gland cancer Peking Union Medical College Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as pyrrolizidine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05898373 ↗